High Point Advisor Group LLC Paratek Pharmaceuticals, Inc. Transaction History

High Point Advisor Group LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.73 - $3.09 $60 - $108	-35 Reduced 0.34%	10,242 $22,000
Q3 2021 Nov 15, 2021	SELL	$4.7 - $7.24 $20,689 - $31,870	-4,402 Reduced 29.99%	10,277 $50,000
Q2 2021 Jul 29, 2021	SELL	$6.81 - $10.93 $4,085 - $6,558	-600 Reduced 3.93%	14,679 $100,000
Q4 2020 Feb 10, 2021	BUY	$4.58 - $7.14 $503 - $785	110 Added 0.73%	15,279 $122,000
Q1 2020 May 01, 2020	BUY	$2.67 - $4.97 $40,325 - $75,061	15,103 Added 22883.33%	15,169 $66,000
Q1 2020 Apr 27, 2020	SELL	$2.67 - $4.97 $39,265 - $73,088	-14,706 Reduced 99.55%	66 $15.2 Million
Q3 2019 Nov 12, 2019	BUY	$3.08 - $5.76 $14,288 - $26,720	4,639 Added 45.78%	14,772 $60,000
Q2 2019 Aug 15, 2019	BUY	$3.47 - $6.32 $35,161 - $64,040	10,133 New	10,133 $34,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of High Point Advisor Group LLC, based on Form 13F filings with the SEC.

Stay updated on High Point Advisor Group LLC with notifications on news.